Vertex Pharmaceuticals Reports 8% Revenue Growth to $2.99 Billion in Q1 2026

Vertex Pharmaceuticals Incorporated reported a significant increase in financial performance for the first quarter of 2026, with total revenues reaching $2.99 billion, up 8% from $2.77 billion in the same period last year. The growth was primarily driven by strong sales of its cystic fibrosis (CF) therapies, particularly the newly launched ALYFTREK, which saw revenues soar to $424.4 million from $53.9 million in the previous year. The company also recorded $42.9 million in revenues from CASGEVY, a treatment for sickle cell disease and beta thalassemia, marking a 202% increase compared to the prior year.

In terms of profitability, Vertex reported a net income of $1.03 billion, or $4.02 per diluted share, compared to $646.3 million, or $2.49 per diluted share, in the first quarter of 2025. This increase in net income was attributed to a reduction in total costs and expenses, which decreased by 14% to $1.85 billion, down from $2.14 billion a year earlier. The decrease was largely due to the absence of an intangible asset impairment charge that had impacted the previous year’s results, as well as lower research and development expenses.

Operationally, Vertex has made strides in expanding its market presence. The company reported that approximately 800 new patients in the U.S. are now eligible for its CF treatments following recent FDA label extensions for ALYFTREK and TRIKAFTA. Additionally, the company has secured reimbursement agreements for ALYFTREK in several countries, including Scotland and Spain, and is working to expand access in more regions. The total cash, cash equivalents, and marketable securities increased to $13.0 billion as of March 31, 2026, up from $12.3 billion at the end of 2025, reflecting strong cash flows from operations.

Looking ahead, Vertex is focused on advancing its pipeline of therapies, including the anticipated launch of povetacicept for IgA nephropathy. The company is also preparing for regulatory submissions for CASGEVY in younger pediatric populations. Vertex's strategy includes continued investment in research and development to support its diverse pipeline, which targets various serious diseases beyond CF, such as type 1 diabetes and neuropathic pain. The company remains committed to leveraging its financial strength to drive growth and innovation in the biopharmaceutical sector.